Swathi Gopishetty
Hematology & Oncology · Royal Oak, MINPI 1811316052
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,535 of the $2,491 with a category attached, or 61.6%. It is spread thinly across 25 manufacturers, the largest accounting for just 14.5%. 2025 is the largest year on record at $1,075, more than ten times the $103 reported in 2019.
Across 48 payments — averaging $51.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$361
- Lilly USA, LLC$288
- AstraZeneca$234
- Novartis$231
- Incyte Corporation$185
- Sobi, Inc$160
- plus $1K from 19 others
What the payments were for
- Food & beverage$1,53562%
- Education$95638%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $361 |
| Lilly USA, LLC | 3 | $288 |
| AstraZeneca(2 entities) | 4 | $234 |
| Novartis | 6 | $231 |
| Incyte Corporation | 2 | $185 |
| Sobi, Inc | 2 | $160 |
| Novocure Inc. | 1 | $132 |
| GSK | 1 | $126 |
| Pharmaessentia USA Corporation | 1 | $122 |
| Johnson & Johnson(2 entities) | 2 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $89 |
| Exelixis Inc. | 2 | $75 |
| Sanofi | 2 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Mylan Specialty L.p. | 2 | $36 |
| Recordati_rare_diseases_inc. | 1 | $36 |
| Genentech USA, Inc. | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Melinta Therapeutics, LLC | 2 | $28 |
| Merck | 1 | $27 |
| ADC Therapeutics America, Inc. | 1 | $27 |
| Geron Corporation | 1 | $23 |
| Deciphera Pharmaceuticals Inc. | 1 | $17 |
| Immunogen, Inc. | 1 | $16 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,491 in reported general payments places this provider in the 55th percentile of 282 hematology & oncology providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 12 | $8,939 |
| Dexamethasone | 15 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $111 | $8,93912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Royal Oak
- Samer BallouzRoyal Oak$29K
- Matthew CotantRoyal Oak$17K
- Elisa QuirozRoyal Oak$13K
- Laura NadeauRoyal Oak$11K
- Martin TapiaRoyal Oak$10K
- Deepa JagtapRoyal Oak$9K
- Ishmael JaiyesimiRoyal Oak$9K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.